Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.1% – Should You Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price was up 7.1% during trading on Wednesday . The stock traded as high as $8.60 and last traded at $8.6770. Approximately 1,429,118 shares were traded during trading, a decline of 72% from the average daily volume of 5,160,131 shares. The stock had previously closed at $8.10.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTLA. Barclays decreased their target price on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada lowered their price objective on shares of Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Finally, Jones Trading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and an average target price of $18.43.

Intellia Therapeutics Price Performance

The business has a 50-day simple moving average of $15.47 and a 200 day simple moving average of $12.54. The firm has a market cap of $1.11 billion, a PE ratio of -2.25 and a beta of 2.13.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. The company had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue was up 51.6% on a year-over-year basis. During the same period in the previous year, the company posted ($1.34) EPS. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 1,871 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of NTLA. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics in the second quarter valued at about $26,000. Blue Bell Private Wealth Management LLC purchased a new position in Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd bought a new position in Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Whipplewood Advisors LLC boosted its stake in Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.